Your browser doesn't support javascript.
The Impact of COVID-19 on Hospitalised COPD Exacerbations in Malta.
Farrugia, Yvette; Spiteri Meilak, Bernard Paul; Grech, Neil; Asciak, Rachelle; Camilleri, Liberato; Montefort, Stephen; Zammit, Christopher.
  • Farrugia Y; Mater Dei Hospital, Triq id-Donaturi tad-Demm, Msida MSD2090, Malta.
  • Spiteri Meilak BP; Mater Dei Hospital, Triq id-Donaturi tad-Demm, Msida MSD2090, Malta.
  • Grech N; Mater Dei Hospital, Triq id-Donaturi tad-Demm, Msida MSD2090, Malta.
  • Asciak R; Mater Dei Hospital, Triq id-Donaturi tad-Demm, Msida MSD2090, Malta.
  • Camilleri L; Mater Dei Hospital, Triq id-Donaturi tad-Demm, Msida MSD2090, Malta.
  • Montefort S; Mater Dei Hospital, Triq id-Donaturi tad-Demm, Msida MSD2090, Malta.
  • Zammit C; Mater Dei Hospital, Triq id-Donaturi tad-Demm, Msida MSD2090, Malta.
Pulm Med ; 2021: 5533123, 2021.
Article in English | MEDLINE | ID: covidwho-1288475
ABSTRACT

METHOD:

Data was collected retrospectively from electronic hospital records during the periods 1st March until 10th May in 2019 and 2020.

RESULTS:

There was a marked decrease in AECOPD admissions in 2020, with a 54.2% drop in admissions (n = 119 in 2020 vs. n = 259 in 2019). There was no significant difference in patient demographics or medical comorbidities. In 2020, there was a significantly lower number of patients with AECOPD who received nebulised medications during admission (60.4% in 2020 vs. 84.9% in 2019; p ≤ 0.001). There were also significantly lower numbers of AECOPD patients admitted in 2020 who received controlled oxygen via venturi masks (69.0% in 2020 vs. 84.5% in 2019; p = 0.006). There was a significant increase in inpatient mortality in 2020 (19.3% [n = 23] and 8.4% [n = 22] for 2020 and 2019, respectively, p = 0.003). Year was found to be the best predictor of mortality outcome (p = 0.001). The lack of use of SABA pre-admission treatment (p = 0.002), active malignancy (p = 0.003), and increased length of hospital stay (p = 0.046) were also found to be predictors of mortality for AECOPD patients; however, these parameters were unchanged between 2019 and 2020 and therefore could not account for the increase in mortality.

CONCLUSIONS:

There was a decrease in the number of admissions with AECOPD in 2020 during the COVID-19 pandemic, when compared to 2019. The year 2020 proved to be a significant predictor for inpatient mortality, with a significant increase in mortality in 2020. The decrease in nebuliser and controlled oxygen treatment noted in the study period did not prove to be a significant predictor of mortality when corrected for other variables. Therefore, the difference in mortality cannot be explained with certainty in this retrospective cohort study.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pulmonary Disease, Chronic Obstructive / COVID-19 / Hospitalization Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male Country/Region as subject: Europa Language: English Journal: Pulm Med Year: 2021 Document Type: Article Affiliation country: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pulmonary Disease, Chronic Obstructive / COVID-19 / Hospitalization Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male Country/Region as subject: Europa Language: English Journal: Pulm Med Year: 2021 Document Type: Article Affiliation country: 2021